clinicaltrialvanguard

Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials

Arcus Biosciences has $694M in cash to advance its pipeline through pivotal trials, including the Phase 3 PRISM-1 study of ...
clinicaltrialvanguard

When Payer Status Becomes a Protocol Variable: What the Medicare Advantage Transplant Gap Means for ESKD Trial Enrollment

MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a ...
clinicaltrialvanguardOpinion

Pelacarsen Lowered the Biomarker. It Did Not Save Lives. Now What?

Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B ...
clinicaltrialvanguard

YPrime Names Greg Wellbrock Chief Data and AI Officer

YPrime names Greg Wellbrock Chief Data and AI Officer to lead unified data and AI strategy across its clinical trial ...